Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,147
archived clinical trials in
Asthma

Chronic Dosing, Cross-Over Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent Asthma
A Randomized, Double-Blind, Chronic Dosing (4 Weeks), Four-Period, Five-Treatment, Incomplete Block, Cross-Over, Multi-Center Study to Assess the Efficacy and Safety of Four Doses of Budesonide Inhalation Aerosol (BD MDI, PT008) Relative to Placebo MDI in Adult Subjects With Mild to Moderate Persistent Asthma
Status: Enrolling
Updated:  2/17/2016
Pearl Therapeutics Study Site
2242
mi
from 98109
Spartanburg, SC
Chronic Dosing, Cross-Over Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent Asthma
A Randomized, Double-Blind, Chronic Dosing (4 Weeks), Four-Period, Five-Treatment, Incomplete Block, Cross-Over, Multi-Center Study to Assess the Efficacy and Safety of Four Doses of Budesonide Inhalation Aerosol (BD MDI, PT008) Relative to Placebo MDI in Adult Subjects With Mild to Moderate Persistent Asthma
Status: Enrolling
Updated: 2/17/2016
Pearl Therapeutics Study Site
2242
mi
from 98109
Spartanburg, SC
Click here to add this to my saved trials
Chronic Dosing, Cross-Over Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent Asthma
A Randomized, Double-Blind, Chronic Dosing (4 Weeks), Four-Period, Five-Treatment, Incomplete Block, Cross-Over, Multi-Center Study to Assess the Efficacy and Safety of Four Doses of Budesonide Inhalation Aerosol (BD MDI, PT008) Relative to Placebo MDI in Adult Subjects With Mild to Moderate Persistent Asthma
Status: Enrolling
Updated:  2/17/2016
Pearl Therapeutics Study Site
949
mi
from 98109
Rapid CIty, SD
Chronic Dosing, Cross-Over Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent Asthma
A Randomized, Double-Blind, Chronic Dosing (4 Weeks), Four-Period, Five-Treatment, Incomplete Block, Cross-Over, Multi-Center Study to Assess the Efficacy and Safety of Four Doses of Budesonide Inhalation Aerosol (BD MDI, PT008) Relative to Placebo MDI in Adult Subjects With Mild to Moderate Persistent Asthma
Status: Enrolling
Updated: 2/17/2016
Pearl Therapeutics Study Site
949
mi
from 98109
Rapid CIty, SD
Click here to add this to my saved trials
Chronic Dosing, Cross-Over Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent Asthma
A Randomized, Double-Blind, Chronic Dosing (4 Weeks), Four-Period, Five-Treatment, Incomplete Block, Cross-Over, Multi-Center Study to Assess the Efficacy and Safety of Four Doses of Budesonide Inhalation Aerosol (BD MDI, PT008) Relative to Placebo MDI in Adult Subjects With Mild to Moderate Persistent Asthma
Status: Enrolling
Updated:  2/17/2016
Pearl Therapeutics Study Site
2029
mi
from 98109
Tullahoma, TN
Chronic Dosing, Cross-Over Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent Asthma
A Randomized, Double-Blind, Chronic Dosing (4 Weeks), Four-Period, Five-Treatment, Incomplete Block, Cross-Over, Multi-Center Study to Assess the Efficacy and Safety of Four Doses of Budesonide Inhalation Aerosol (BD MDI, PT008) Relative to Placebo MDI in Adult Subjects With Mild to Moderate Persistent Asthma
Status: Enrolling
Updated: 2/17/2016
Pearl Therapeutics Study Site
2029
mi
from 98109
Tullahoma, TN
Click here to add this to my saved trials
Chronic Dosing, Cross-Over Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent Asthma
A Randomized, Double-Blind, Chronic Dosing (4 Weeks), Four-Period, Five-Treatment, Incomplete Block, Cross-Over, Multi-Center Study to Assess the Efficacy and Safety of Four Doses of Budesonide Inhalation Aerosol (BD MDI, PT008) Relative to Placebo MDI in Adult Subjects With Mild to Moderate Persistent Asthma
Status: Enrolling
Updated:  2/17/2016
Pearl Therapeutics Study Site
1377
mi
from 98109
El Paso, TX
Chronic Dosing, Cross-Over Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent Asthma
A Randomized, Double-Blind, Chronic Dosing (4 Weeks), Four-Period, Five-Treatment, Incomplete Block, Cross-Over, Multi-Center Study to Assess the Efficacy and Safety of Four Doses of Budesonide Inhalation Aerosol (BD MDI, PT008) Relative to Placebo MDI in Adult Subjects With Mild to Moderate Persistent Asthma
Status: Enrolling
Updated: 2/17/2016
Pearl Therapeutics Study Site
1377
mi
from 98109
El Paso, TX
Click here to add this to my saved trials
Chronic Dosing, Cross-Over Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent Asthma
A Randomized, Double-Blind, Chronic Dosing (4 Weeks), Four-Period, Five-Treatment, Incomplete Block, Cross-Over, Multi-Center Study to Assess the Efficacy and Safety of Four Doses of Budesonide Inhalation Aerosol (BD MDI, PT008) Relative to Placebo MDI in Adult Subjects With Mild to Moderate Persistent Asthma
Status: Enrolling
Updated:  2/17/2016
Pearl Therapeutics Study Site
1890
mi
from 98109
Houston, TX
Chronic Dosing, Cross-Over Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent Asthma
A Randomized, Double-Blind, Chronic Dosing (4 Weeks), Four-Period, Five-Treatment, Incomplete Block, Cross-Over, Multi-Center Study to Assess the Efficacy and Safety of Four Doses of Budesonide Inhalation Aerosol (BD MDI, PT008) Relative to Placebo MDI in Adult Subjects With Mild to Moderate Persistent Asthma
Status: Enrolling
Updated: 2/17/2016
Pearl Therapeutics Study Site
1890
mi
from 98109
Houston, TX
Click here to add this to my saved trials
Chronic Dosing, Cross-Over Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent Asthma
A Randomized, Double-Blind, Chronic Dosing (4 Weeks), Four-Period, Five-Treatment, Incomplete Block, Cross-Over, Multi-Center Study to Assess the Efficacy and Safety of Four Doses of Budesonide Inhalation Aerosol (BD MDI, PT008) Relative to Placebo MDI in Adult Subjects With Mild to Moderate Persistent Asthma
Status: Enrolling
Updated:  2/17/2016
Pearl Therapeutics Study Site
1673
mi
from 98109
Plano, TX
Chronic Dosing, Cross-Over Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent Asthma
A Randomized, Double-Blind, Chronic Dosing (4 Weeks), Four-Period, Five-Treatment, Incomplete Block, Cross-Over, Multi-Center Study to Assess the Efficacy and Safety of Four Doses of Budesonide Inhalation Aerosol (BD MDI, PT008) Relative to Placebo MDI in Adult Subjects With Mild to Moderate Persistent Asthma
Status: Enrolling
Updated: 2/17/2016
Pearl Therapeutics Study Site
1673
mi
from 98109
Plano, TX
Click here to add this to my saved trials
Chronic Dosing, Cross-Over Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent Asthma
A Randomized, Double-Blind, Chronic Dosing (4 Weeks), Four-Period, Five-Treatment, Incomplete Block, Cross-Over, Multi-Center Study to Assess the Efficacy and Safety of Four Doses of Budesonide Inhalation Aerosol (BD MDI, PT008) Relative to Placebo MDI in Adult Subjects With Mild to Moderate Persistent Asthma
Status: Enrolling
Updated:  2/17/2016
Pearl Therapeutics Study Site
1787
mi
from 98109
San Antonio, TX
Chronic Dosing, Cross-Over Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent Asthma
A Randomized, Double-Blind, Chronic Dosing (4 Weeks), Four-Period, Five-Treatment, Incomplete Block, Cross-Over, Multi-Center Study to Assess the Efficacy and Safety of Four Doses of Budesonide Inhalation Aerosol (BD MDI, PT008) Relative to Placebo MDI in Adult Subjects With Mild to Moderate Persistent Asthma
Status: Enrolling
Updated: 2/17/2016
Pearl Therapeutics Study Site
1787
mi
from 98109
San Antonio, TX
Click here to add this to my saved trials
Chronic Dosing, Cross-Over Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent Asthma
A Randomized, Double-Blind, Chronic Dosing (4 Weeks), Four-Period, Five-Treatment, Incomplete Block, Cross-Over, Multi-Center Study to Assess the Efficacy and Safety of Four Doses of Budesonide Inhalation Aerosol (BD MDI, PT008) Relative to Placebo MDI in Adult Subjects With Mild to Moderate Persistent Asthma
Status: Enrolling
Updated:  2/17/2016
Pearl Therapeutics Study Site
24
mi
from 98109
Everett, WA
Chronic Dosing, Cross-Over Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent Asthma
A Randomized, Double-Blind, Chronic Dosing (4 Weeks), Four-Period, Five-Treatment, Incomplete Block, Cross-Over, Multi-Center Study to Assess the Efficacy and Safety of Four Doses of Budesonide Inhalation Aerosol (BD MDI, PT008) Relative to Placebo MDI in Adult Subjects With Mild to Moderate Persistent Asthma
Status: Enrolling
Updated: 2/17/2016
Pearl Therapeutics Study Site
24
mi
from 98109
Everett, WA
Click here to add this to my saved trials
Assessment and Evaluation of Pharmacokinetic Profile of E004 in Healthy Adults
Assessment and Evaluation of Pharmacokinetic Profile of E004 in Healthy Adults (A Randomized, Evaluator-Blind, Single-Dose, Two Arm, Crossover, PK Study in Healthy Volunteers)
Status: Enrolling
Updated:  2/18/2016
West Coast Clinical Trials, LLC
980
mi
from 98109
Cypress, CA
Assessment and Evaluation of Pharmacokinetic Profile of E004 in Healthy Adults
Assessment and Evaluation of Pharmacokinetic Profile of E004 in Healthy Adults (A Randomized, Evaluator-Blind, Single-Dose, Two Arm, Crossover, PK Study in Healthy Volunteers)
Status: Enrolling
Updated: 2/18/2016
West Coast Clinical Trials, LLC
980
mi
from 98109
Cypress, CA
Click here to add this to my saved trials
Epinephrine Inhalation Aerosol USP, CLINICAL STUDY-B3 FOR ASSESSMENT OF PHARMACOKINETICS
CLINICAL STUDY-B3 FOR ASSESSMENT OF PHARMACOKINETICS, A Randomized, Evaluator-Blind, Single-Dose, Three Arm, Crossover,PK Study in Healthy Volunteers
Status: Enrolling
Updated:  2/18/2016
Amphastar Study Site 1
980
mi
from 98109
Cypress, CA
Epinephrine Inhalation Aerosol USP, CLINICAL STUDY-B3 FOR ASSESSMENT OF PHARMACOKINETICS
CLINICAL STUDY-B3 FOR ASSESSMENT OF PHARMACOKINETICS, A Randomized, Evaluator-Blind, Single-Dose, Three Arm, Crossover,PK Study in Healthy Volunteers
Status: Enrolling
Updated: 2/18/2016
Amphastar Study Site 1
980
mi
from 98109
Cypress, CA
Click here to add this to my saved trials
Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis
Randomized, Multicentric, Controlled Study on the Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis
Status: Enrolling
Updated:  2/23/2016
Hamzavi Dermatology/Dermatology Specialists of Canton
1913
mi
from 98109
Canton, MI
Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis
Randomized, Multicentric, Controlled Study on the Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis
Status: Enrolling
Updated: 2/23/2016
Hamzavi Dermatology/Dermatology Specialists of Canton
1913
mi
from 98109
Canton, MI
Click here to add this to my saved trials
Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis
Randomized, Multicentric, Controlled Study on the Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis
Status: Enrolling
Updated:  2/23/2016
Hamzavi Dermatology
1939
mi
from 98109
Fort Gratiot, MI
Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis
Randomized, Multicentric, Controlled Study on the Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis
Status: Enrolling
Updated: 2/23/2016
Hamzavi Dermatology
1939
mi
from 98109
Fort Gratiot, MI
Click here to add this to my saved trials
Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis
Randomized, Multicentric, Controlled Study on the Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis
Status: Enrolling
Updated:  2/23/2016
Lynderm Research
2062
mi
from 98109
Markham,
Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis
Randomized, Multicentric, Controlled Study on the Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis
Status: Enrolling
Updated: 2/23/2016
Lynderm Research
2062
mi
from 98109
Markham,
Click here to add this to my saved trials
Inhaled Fluticasone Effects on Upper Airway Patency in Obstructive Lung Disease
Inhaled Fluticasone Effects on Upper Airway Patency in Obstructive Lung Disease
Status: Enrolling
Updated:  2/24/2016
William S. Middleton Memorial Veterans Hospital, Madison, WI
1617
mi
from 98109
Madison, WI
Inhaled Fluticasone Effects on Upper Airway Patency in Obstructive Lung Disease
Inhaled Fluticasone Effects on Upper Airway Patency in Obstructive Lung Disease
Status: Enrolling
Updated: 2/24/2016
William S. Middleton Memorial Veterans Hospital, Madison, WI
1617
mi
from 98109
Madison, WI
Click here to add this to my saved trials
Long-acting Beta Agonist Step Down Study
Long-acting Beta Agonist Step Down Study
Status: Enrolling
Updated:  2/26/2016
Baylor College of Medicine
1890
mi
from 98109
Houston, TX
Long-acting Beta Agonist Step Down Study
Long-acting Beta Agonist Step Down Study
Status: Enrolling
Updated: 2/26/2016
Baylor College of Medicine
1890
mi
from 98109
Houston, TX
Click here to add this to my saved trials
Long-acting Beta Agonist Step Down Study
Long-acting Beta Agonist Step Down Study
Status: Enrolling
Updated:  2/26/2016
Duke Univ Med Ctr
2341
mi
from 98109
Durham, NC
Long-acting Beta Agonist Step Down Study
Long-acting Beta Agonist Step Down Study
Status: Enrolling
Updated: 2/26/2016
Duke Univ Med Ctr
2341
mi
from 98109
Durham, NC
Click here to add this to my saved trials
Long-acting Beta Agonist Step Down Study
Long-acting Beta Agonist Step Down Study
Status: Enrolling
Updated:  2/26/2016
Hofstra North Shore-LIJ School of Medicine
2416
mi
from 98109
New Hyde Park, NY
Long-acting Beta Agonist Step Down Study
Long-acting Beta Agonist Step Down Study
Status: Enrolling
Updated: 2/26/2016
Hofstra North Shore-LIJ School of Medicine
2416
mi
from 98109
New Hyde Park, NY
Click here to add this to my saved trials
Long-acting Beta Agonist Step Down Study
Long-acting Beta Agonist Step Down Study
Status: Enrolling
Updated:  2/26/2016
Louisiana State University Health Sciences Center, The Ernest N. Morial Asthma, Allergy and Respiratory Disease Center
2099
mi
from 98109
New Orleans, LA
Long-acting Beta Agonist Step Down Study
Long-acting Beta Agonist Step Down Study
Status: Enrolling
Updated: 2/26/2016
Louisiana State University Health Sciences Center, The Ernest N. Morial Asthma, Allergy and Respiratory Disease Center
2099
mi
from 98109
New Orleans, LA
Click here to add this to my saved trials
Long-acting Beta Agonist Step Down Study
Long-acting Beta Agonist Step Down Study
Status: Enrolling
Updated:  2/26/2016
Maria Fareri Children's Hospital at Westchester Medical Center and New York Medical College
2401
mi
from 98109
Valhalla, NY
Long-acting Beta Agonist Step Down Study
Long-acting Beta Agonist Step Down Study
Status: Enrolling
Updated: 2/26/2016
Maria Fareri Children's Hospital at Westchester Medical Center and New York Medical College
2401
mi
from 98109
Valhalla, NY
Click here to add this to my saved trials
Long-acting Beta Agonist Step Down Study
Long-acting Beta Agonist Step Down Study
Status: Enrolling
Updated:  2/26/2016
National Jewish Health
1022
mi
from 98109
Denver, CO
Long-acting Beta Agonist Step Down Study
Long-acting Beta Agonist Step Down Study
Status: Enrolling
Updated: 2/26/2016
National Jewish Health
1022
mi
from 98109
Denver, CO
Click here to add this to my saved trials
Long-acting Beta Agonist Step Down Study
Long-acting Beta Agonist Step Down Study
Status: Enrolling
Updated:  2/26/2016
Nemours Children's Clinic
2452
mi
from 98109
Jacksonville, FL
Long-acting Beta Agonist Step Down Study
Long-acting Beta Agonist Step Down Study
Status: Enrolling
Updated: 2/26/2016
Nemours Children's Clinic
2452
mi
from 98109
Jacksonville, FL
Click here to add this to my saved trials
Long-acting Beta Agonist Step Down Study
Long-acting Beta Agonist Step Down Study
Status: Enrolling
Updated:  2/26/2016
New York University School of Medicine
2402
mi
from 98109
New York, NY
Long-acting Beta Agonist Step Down Study
Long-acting Beta Agonist Step Down Study
Status: Enrolling
Updated: 2/26/2016
New York University School of Medicine
2402
mi
from 98109
New York, NY
Click here to add this to my saved trials
Long-acting Beta Agonist Step Down Study
Long-acting Beta Agonist Step Down Study
Status: Enrolling
Updated:  2/26/2016
Northern New England Consortium
2324
mi
from 98109
Colchester, VT
Long-acting Beta Agonist Step Down Study
Long-acting Beta Agonist Step Down Study
Status: Enrolling
Updated: 2/26/2016
Northern New England Consortium
2324
mi
from 98109
Colchester, VT
Click here to add this to my saved trials
Long-acting Beta Agonist Step Down Study
Long-acting Beta Agonist Step Down Study
Status: Enrolling
Updated:  2/26/2016
St. Vincent Healthcare
1868
mi
from 98109
Indianapolis, IN
Long-acting Beta Agonist Step Down Study
Long-acting Beta Agonist Step Down Study
Status: Enrolling
Updated: 2/26/2016
St. Vincent Healthcare
1868
mi
from 98109
Indianapolis, IN
Click here to add this to my saved trials
Long-acting Beta Agonist Step Down Study
Long-acting Beta Agonist Step Down Study
Status: Enrolling
Updated:  2/26/2016
St. Vincent Hospital and Health Care Center
1862
mi
from 98109
Indianapolis, IN
Long-acting Beta Agonist Step Down Study
Long-acting Beta Agonist Step Down Study
Status: Enrolling
Updated: 2/26/2016
St. Vincent Hospital and Health Care Center
1862
mi
from 98109
Indianapolis, IN
Click here to add this to my saved trials
Long-acting Beta Agonist Step Down Study
Long-acting Beta Agonist Step Down Study
Status: Enrolling
Updated:  2/26/2016
Illinois Consortium
1733
mi
from 98109
Chicago, IL
Long-acting Beta Agonist Step Down Study
Long-acting Beta Agonist Step Down Study
Status: Enrolling
Updated: 2/26/2016
Illinois Consortium
1733
mi
from 98109
Chicago, IL
Click here to add this to my saved trials
Long-acting Beta Agonist Step Down Study
Long-acting Beta Agonist Step Down Study
Status: Enrolling
Updated:  2/26/2016
University of Arizona, Arizona Respiratory Center
1220
mi
from 98109
Tucson, AZ
Long-acting Beta Agonist Step Down Study
Long-acting Beta Agonist Step Down Study
Status: Enrolling
Updated: 2/26/2016
University of Arizona, Arizona Respiratory Center
1220
mi
from 98109
Tucson, AZ
Click here to add this to my saved trials
Long-acting Beta Agonist Step Down Study
Long-acting Beta Agonist Step Down Study
Status: Enrolling
Updated:  2/26/2016
University of Miami/University of South Florida
2523
mi
from 98109
Tampa, FL
Long-acting Beta Agonist Step Down Study
Long-acting Beta Agonist Step Down Study
Status: Enrolling
Updated: 2/26/2016
University of Miami/University of South Florida
2523
mi
from 98109
Tampa, FL
Click here to add this to my saved trials
Long-acting Beta Agonist Step Down Study
Long-acting Beta Agonist Step Down Study
Status: Enrolling
Updated:  2/26/2016
University of Missouri, Kansas City School of Medicine
1503
mi
from 98109
Kansas City, MO
Long-acting Beta Agonist Step Down Study
Long-acting Beta Agonist Step Down Study
Status: Enrolling
Updated: 2/26/2016
University of Missouri, Kansas City School of Medicine
1503
mi
from 98109
Kansas City, MO
Click here to add this to my saved trials
Long-acting Beta Agonist Step Down Study
Long-acting Beta Agonist Step Down Study
Status: Enrolling
Updated:  2/26/2016
University of Virginia
2283
mi
from 98109
Charlottesville, VA
Long-acting Beta Agonist Step Down Study
Long-acting Beta Agonist Step Down Study
Status: Enrolling
Updated: 2/26/2016
University of Virginia
2283
mi
from 98109
Charlottesville, VA
Click here to add this to my saved trials
Long-acting Beta Agonist Step Down Study
Long-acting Beta Agonist Step Down Study
Status: Enrolling
Updated:  2/26/2016
Washington University/St. Louis University
1720
mi
from 98109
St. Louis, MO
Long-acting Beta Agonist Step Down Study
Long-acting Beta Agonist Step Down Study
Status: Enrolling
Updated: 2/26/2016
Washington University/St. Louis University
1720
mi
from 98109
St. Louis, MO
Click here to add this to my saved trials
Long-acting Beta Agonist Step Down Study
Long-acting Beta Agonist Step Down Study
Status: Enrolling
Updated:  2/26/2016
University of California, San Diego
1049
mi
from 98109
San Diego, CA
Long-acting Beta Agonist Step Down Study
Long-acting Beta Agonist Step Down Study
Status: Enrolling
Updated: 2/26/2016
University of California, San Diego
1049
mi
from 98109
San Diego, CA
Click here to add this to my saved trials
Long-acting Beta Agonist Step Down Study
Long-acting Beta Agonist Step Down Study
Status: Enrolling
Updated:  2/26/2016
Ohio State University Medical Center
2007
mi
from 98109
Columbus, OH
Long-acting Beta Agonist Step Down Study
Long-acting Beta Agonist Step Down Study
Status: Enrolling
Updated: 2/26/2016
Ohio State University Medical Center
2007
mi
from 98109
Columbus, OH
Click here to add this to my saved trials
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated:  3/3/2016
Novartis Investigative Site
1117
mi
from 98109
Scottsdale, AZ
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated: 3/3/2016
Novartis Investigative Site
1117
mi
from 98109
Scottsdale, AZ
Click here to add this to my saved trials
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated:  3/3/2016
Novartis Investigative Site
1042
mi
from 98109
Encinitas, CA
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated: 3/3/2016
Novartis Investigative Site
1042
mi
from 98109
Encinitas, CA
Click here to add this to my saved trials
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated:  3/3/2016
Novartis Investigative Site
987
mi
from 98109
Huntington Beach, CA
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated: 3/3/2016
Novartis Investigative Site
987
mi
from 98109
Huntington Beach, CA
Click here to add this to my saved trials
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated:  3/3/2016
Novartis Investigative site
979
mi
from 98109
Los Angeles, CA
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated: 3/3/2016
Novartis Investigative site
979
mi
from 98109
Los Angeles, CA
Click here to add this to my saved trials
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated:  3/3/2016
Novartis Investigational Site
984
mi
from 98109
Orange, CA
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated: 3/3/2016
Novartis Investigational Site
984
mi
from 98109
Orange, CA
Click here to add this to my saved trials
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated:  3/3/2016
Novartis Investigative Site
980
mi
from 98109
Riverside, CA
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated: 3/3/2016
Novartis Investigative Site
980
mi
from 98109
Riverside, CA
Click here to add this to my saved trials
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated:  3/3/2016
Novartis Investigative Site
1059
mi
from 98109
San Diego, CA
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated: 3/3/2016
Novartis Investigative Site
1059
mi
from 98109
San Diego, CA
Click here to add this to my saved trials
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated:  3/3/2016
Novartis Investigative Site
1059
mi
from 98109
San Diego, CA
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated: 3/3/2016
Novartis Investigative Site
1059
mi
from 98109
San Diego, CA
Click here to add this to my saved trials
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated:  3/3/2016
Novartis Investigative Site
713
mi
from 98109
San Jose, CA
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated: 3/3/2016
Novartis Investigative Site
713
mi
from 98109
San Jose, CA
Click here to add this to my saved trials
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated:  3/3/2016
Novartis Investigative Site
694
mi
from 98109
San Mateo, CA
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated: 3/3/2016
Novartis Investigative Site
694
mi
from 98109
San Mateo, CA
Click here to add this to my saved trials
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated:  3/3/2016
Novartis Investigative Site
669
mi
from 98109
Stockton, CA
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated: 3/3/2016
Novartis Investigative Site
669
mi
from 98109
Stockton, CA
Click here to add this to my saved trials
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated:  3/3/2016
Novartis
1023
mi
from 98109
Denver, CO
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated: 3/3/2016
Novartis
1023
mi
from 98109
Denver, CO
Click here to add this to my saved trials
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated:  3/3/2016
Novartis Investigative Site
2554
mi
from 98109
Sarasota, FL
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated: 3/3/2016
Novartis Investigative Site
2554
mi
from 98109
Sarasota, FL
Click here to add this to my saved trials
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated:  3/3/2016
Novartis Investigative Site
2404
mi
from 98109
Savannah, GA
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated: 3/3/2016
Novartis Investigative Site
2404
mi
from 98109
Savannah, GA
Click here to add this to my saved trials
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated:  3/3/2016
Novartis Investigative Site
1724
mi
from 98109
River Forest, IL
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated: 3/3/2016
Novartis Investigative Site
1724
mi
from 98109
River Forest, IL
Click here to add this to my saved trials
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated:  3/3/2016
Novartis Investigative Site
2517
mi
from 98109
Bangor, ME
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated: 3/3/2016
Novartis Investigative Site
2517
mi
from 98109
Bangor, ME
Click here to add this to my saved trials
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated:  3/3/2016
Novartis Investigative Site
2317
mi
from 98109
Wheaton, MD
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated: 3/3/2016
Novartis Investigative Site
2317
mi
from 98109
Wheaton, MD
Click here to add this to my saved trials